A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

2024-512689-32-00 Protocol 67856633LYM1002 Human pharmacology (Phase I) - Other Ended

Start 15 Jul 2021 · End 13 Feb 2025 · Status Ended · 2 EU/EEA countries · 4 sites · Protocol 67856633LYM1002

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 12
Countries 2
Sites 4

Non-Hodgkin lymphoma and chronic lymphocytic leukemia

Key facts

Sponsor
Janssen Cilag International
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
15 Jul 2021 → 13 Feb 2025
Decision date (initial)
2024-07-01
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-512689-32-00
EudraCT number
2021-000191-12

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Non-Hodgkin lymphoma and chronic lymphocytic leukemia

VersionLevelCodeTermSystem organ class
23.1 LLT 10084346 B-cell non-Hodgkin´s lymphoma 100000004848
21.0 LLT 10008976 Chronic lymphocytic leukemia 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen Cilag International

Sponsor organisation
Janssen Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Locations

2 EU/EEA countries · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 2 2
Poland Ended 10 2
Rest of world 0

Investigational sites

France

2 sites · Ended
Institut Paoli Calmettes
Clinical Hematology Unit, 232 Boulevard De Sainte Marguerite, Bp 156, Marseille
Institut Gustave Roussy
Hematology, 114 Rue Edouard Vaillant, 94800, Villejuif

Poland

2 sites · Ended
Pratia S.A.
Centrum Medyczne Pratia Poznan, Ul. Poznanska 14, 60-185, Skorzewo
Pratia S.A.
Pratia MCM, Ul. Pana Tadeusza 2, 30-727, Cracow

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2021-07-15 2025-02-06 2021-07-28 2022-03-31
Poland 2021-08-09 2025-02-13 2021-08-19 2022-04-20

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-23 Poland Acceptable
2024-06-27
2024-07-01